DFSG 2025

Sponsors and exhibition

Days

Hours

Minutes

The DFSG 2025 Meeting has received CVS-ethical approval from MedTech Europe, confirming its compliance with the ethical standards and transparency required

Interested in sponsoring DFSG 2025?

Get contacted by our dedicated sponsorship and
exhibition team to explore your opportunities.

Thank you to our confirmed sponsors

Join us as a sponsor or exhibitor at DFSG 2025 and connect with leading experts dedicated to advancing diabetic foot care. This is your opportunity to engage with a highly specialised audience, showcase your latest solutions, and contribute to discussions in an inspiring environment.

For more details, download the sponsorship prospectus or contact our sponsorship & exhibition manager directly.

Gold sponsors

Pioneering trusted medical solutions to improve the lives we touch.
Convatec is an innovative global medical products and technologies company, focused on solutions for the management of chronic conditions.

We have leading positions in Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by our promise to be forever caring.

Our solutions provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total costs of care.

Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures.

Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden.

Silver sponsor

At AOTI, we are helping all people with chronic conditions get back to living their lives to the fullest.

Our unique multi-modality Topical Wound Oxygen (TWO2) therapy has been proven through Randomized Controlled Trial and Real-World Evidence studies to significantly reduce both Hospitalizations and Amputations over 12 months.

TWO2 can be administered in any clinical setting or self-administered by the patient at home, overcoming common barriers to access and compliance, thus helping to advance health equity, while improving outcomes and reducing costs.

PVR MED is pioneering a new standard of care for diabetic foot complications by addressing the root cause: Microvascular Dysfunction (MVD).

Our first-in-class, non-invasive physiological therapy is backed by a comprehensive portfolio of clinical evidence, including placebo-controlled RCTs, demonstrating a profound effect on the underlying neurovascular function.

Bronze sponsors

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India.

Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry.

Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

Essity is a leading global hygiene and health company aiming to break barriers to well-being.

With world-renowned brands such as the registered trademarks Leukoplast, Cutimed and JOBST,

Essity is among the global market leaders within its Medical Solutions categories wound care and compression.

At Urgo Medical, our mission is to support Healthcare Professionals to deliver evidence-based advanced wound care treatments from the beginning so that life can start again for patients. Our 1.600 employees are committed every day to making a difference for patients.

Exhibitors

Visit us at DFSG 2025 to learn about SteriPlas, a proven medical device using Premium Cold Plasma to treat chronic diabetic foot ulcers complicated by biofilm. Clinically evidenced to destroy multi-resistant bacteria within biofilm, SteriPlas enables reepithelialisation and wound healing where other treatments fail

Advanced Medical Solutions develops, produces, and distributes integrative solutions (devices, sw + services) for the early and non-invasive diagnostics and therapy of arterial, venous and lymphatic systems with a specific focus on diabetic patients and other groups with cardiovascular risk factors.

The aim is to prevent more serious vascular difficulties thanks to an early detection and application of convenient therapies in time and in the natural environment of the patient.

Bonalive advances the world’s transition to sustainable solutions for infection treatment and bone regeneration. We envision a world where diabetic foot osteomyelitis can be treated without local antibiotics – a smarter world, for a smarter life.

BONESUPPORT™ develops and commercializes bio-ceramic bone graft substitutes based on its CERAMENT® platform, capable of remodeling into bone while eluting antibiotics. With over 140,000 patients treated and ongoing clinical trials, BONESUPPORT is setting new standards in bone repair and infection management.

GCRI is a full-service CRO specialised in Wound Care and Diabetic Foot research.

Tarsos is a MedTech company focused on improving diabetic foot care through innovative, data-driven solutions.

Its flagship system, Senstep, is an in-shoe foot health monitoring solution that supports clinicians in the early detection and prevention of diabetic foot complications. Senstep tracks plantar temperature distribution, a validated marker of inflammation and ulcer risk, and connects seamlessly with a mobile app to provide real-time, actionable data.

By complementing standard care with objective insights, Senstep enables more personalised and proactive management. Identifying early warning signs helps reduce ulcer incidence, prevent amputations, and improve outcomes for at-risk patients.